Pancreatic Cancer Research

ResearcherUniversity of LondonNo recent work listed

Thorsten Hagemann

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5057826311. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 3 papers · 2015: 3 papers · 2016: 1 paper

Papers 10

  1. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? First author DOI 10.1080/2162402x.2015.1112942↗
  2. ADAM8 as a drug target in pancreatic cancer. Co-author DOI 10.1038/ncomms7175↗
  3. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0464↗
  4. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). Co-author DOI 10.1158/1078-0432.ccr-15-0485↗
  5. Inflammatory cytokines in human pancreatic cancer. Last author DOI 10.1016/j.canlet.2013.07.014↗
  6. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. First author DOI 10.1038/cddis.2014.125↗
  7. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13073-014-0105-3↗
  8. Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer Last author DOI 10.1186/2051-1426-1-s1-p215↗
  9. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. Last author DOI 10.4049/jimmunol.1203194↗
  10. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. Last author DOI 10.1172/jci45797↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laura Rosa Brunet · 2 shared papers, 2013–2016 · strength 0.13
  2. Rozita Roshani · 2 shared papers, 2014–2015 · strength 0.11
  3. Eleni Maniati · 3 shared papers, 2011–2015 · strength 0.11
  4. Satvinder Mudan · 1 shared paper, 2016 · strength 0.08
  5. Aurélien Marabelle · 1 shared paper, 2016 · strength 0.08
  6. David Arthur Tuveson · 2 shared papers, 2011–2015 · strength 0.06
  7. Norbert E. Avril · 1 shared paper, 2014 · strength 0.06
  8. C D Hudson · 1 shared paper, 2014 · strength 0.06
  9. Francesca Vena · 1 shared paper, 2015 · strength 0.06
  10. Daniel Hochhauser · 1 shared paper, 2015 · strength 0.06
  11. Androulla Elia · 1 shared paper, 2013 · strength 0.05
  12. Claudine D Neyen · 1 shared paper, 2013 · strength 0.04
  13. Pengju Wang · 1 shared paper, 2015 · strength 0.04
  14. Louisa S. Chard · 1 shared paper, 2015 · strength 0.04
  15. Yaohe Wang · 1 shared paper, 2015 · strength 0.04
  16. Uwe Schlomann · 1 shared paper, 2015 · strength 0.04
  17. Miles Aaron Miller · 1 shared paper, 2015 · strength 0.04
  18. Jörg Walter Bartsch · 1 shared paper, 2015 · strength 0.04
  19. Laurent Dumartin · 1 shared paper, 2014 · strength 0.04
  20. Syed Haider · 1 shared paper, 2014 · strength 0.04
  21. Prabhu Arumugam · 1 shared paper, 2014 · strength 0.04
  22. Jun Wang · 1 shared paper, 2014 · strength 0.04
  23. Claude Chelala · 1 shared paper, 2014 · strength 0.04
  24. Tatjana Crnogorac‐Jurcevic · 1 shared paper, 2014 · strength 0.04
  25. Hemant Mahendrakumar Kocher · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.